Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.48 |
| ▸ | CES1 | P23141 | 10/20 | 0.48 |
| ▸ | CES2 | O00748 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9472467 | 0.81 | FAAH (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9808756 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL17003745 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL136430 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9055251 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2247328 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8345161 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL4300294 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9754734 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1517931 | 0.80 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900364-B1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC (CA) | 2013-09-25 | — | — | EP | disclosed |
| US-8487001-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | PROMETIC PHARMA SMT LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-7745488-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| EP-1900364-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | ProMetic BioSciences Inc. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC PHARMA SMT LIMITED (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1385498-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | Prometic Biosciences Inc. (CA) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083120-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | PROMETIC BIOSCIENCES INC. (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | MYD88, CSF3R, MCTS1 | FAAH 947/4885CES1 334/4885CES2 920/4885 |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | MYD88, CSF3R, MCTS1 | FAAH 947/4885CES1 334/4885CES2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.